ClinicalTrials.gg

Program

VK2735

A development code. Also written as “VK2735 Drug” and “VK2735 Oral”.

Its studies are mostly in Weight Loss · Overweight, led by Viking Therapeutics.

Furthest: phase 3, since Jul 29, 20258 company-led studies, 5 open or runningNext primary completion: May 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Viking Therapeutics85 open or runningphase 3since Jul 29, 2025Jan 10, 2022May 2027phase 1 · NCT07838740

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 10, 2022First study: phase 1 study in Weight LossFirst studyNCT05203237 · 92 enrolled · Australia
  2. Sep 28, 2023Phase 2 study in Weight LossNCT06068946 · 176 enrolled · United States
  3. Feb 10, 2025Phase 2 study in Weight LossNCT06828055 · 280 enrolled · United States
  4. Jul 29, 20252 phase 3 studies in Weight LossNCT07104500, NCT07104383
  5. Sep 9, 2026Phase 1 study in Weight LossNCT07838740 · 270 planned · United States
  6. Oct 5, 20262 phase 3 studies in Weight LossNCT07868939, NCT07868835

Ahead

  1. May 2027Primary completion: phase 1 study in Weight LossNCT07838740
  2. Jul 1, 2027Primary completion: phase 3 study in Weight LossNCT07104500
  3. Jul 1, 2027Primary completion: phase 3 study in Weight LossNCT07104383
  4. Jul 2028Primary completion: phase 3 study in Weight LossNCT07868835

TargetBeta

GIPR →GLP1R →read by rule
“VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily”study text, by rule · the study

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
TirzepatideruleEli Lillyphase 472
retatrutideruleEli Lillyphase 333
olatorepatideHansoh Pharmaceutical Groupphase 312
UBT251The United Laboratories Internationalphase 312
enicepatideHoffmann-La Rochephase 310
NNC0519-0130Novo Nordiskphase 211
BI 3034701Boehringer Ingelheimphase 26
HRS-4729Jiangsu HengRui Medicinephase 25
NA-931rulebiomed-industries-incphase 23

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07868939Weight Loss · United States3RecruitingOct 2028560
NCT07868835Weight Loss · United States3RecruitingJul 2028560
NCT07838740Weight Loss · United States1RecruitingMay 2027270
NCT07104500Weight Loss · United States, Puerto Rico3Active, not recruitingJul 1, 20274,500
NCT07104383Weight Loss · United States, Puerto Rico3Active, not recruitingJul 1, 20271,100
NCT06828055Weight Loss · United States2CompletedJun 24, 2025280
NCT06068946Weight Loss · United States2CompletedFeb 27, 2024176
NCT05203237Weight Loss · Australia1CompletedNov 4, 202492

How it is read

Names in the registry

  • “VK2735”, 6 entries
  • “VK2735 Drug”, 2 entries
  • “VK2735 Oral”, 1 entry

Codes read as this program: VK2735.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.